Study guide

2.3 Critical Care & Emergency Medicine

Board Certified Pharmacotherapy Specialist BCPS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction and Exam Logistics

1.1 About the BCPS Exam & BPS Specialty Board 1.2 Eligibility, Registration, and Pearson VUE Logistics 1.3 Study Strategies & Exam-Taking Skills for BCPS

2 Chapter 2: Therapeutics: Cardiovascular & Pulmonary

2.1 Cardiovascular Pharmacotherapy 2.2 Pulmonology & Respiratory Care 2.3 Critical Care & Emergency Medicine

3 Chapter 3: Therapeutics: Infectious Diseases

3.1 Infectious Diseases: Antimicrobial Stewardship & Pharmacokinetics 3.2 Infectious Diseases: Common & Severe Infections 3.3 Infectious Diseases: Specialty Infections

4 Chapter 4: Therapeutics: Renal, Endocrine & Gastrointestinal

4.1 Nephrology & Renal Pharmacotherapy 4.2 Endocrinology & Diabetes Mellitus 4.3 Gastroenterology & Hepatic Disorders

5 Chapter 5: Therapeutics: Neurology, Psychiatry & Pain Management

5.1 Pain Management & Palliative Care 5.2 Neurologic Pharmacotherapy 5.3 Psychiatric Pharmacotherapy

6 Chapter 6: Therapeutics: Special Populations

6.1 Geriatric Pharmacotherapy & Beers Criteria 6.2 Pediatric & Neonatal Pharmacotherapy 6.3 Women's Health

7 Chapter 7: Therapeutics: Oncology, Nutrition & Immunology

7.1 Oncology & Support Care 7.2 Nutrition Support 7.3 Immunology, Allergy, & Vaccine-Preventable Diseases 7.4 Urologic Disorders: BPH, Overactive Bladder, and Erectile Dysfunction

8 Chapter 8: Patient Care: Therapeutics & Patient Management

8.1 Clinical Assessment & Patient History 8.2 Clinical Pharmacokinetics: Dosing, Clearance, Vd, and TDM 8.3 Therapeutic Implementation & Medication Reconciliation 8.4 Social Determinants of Health in Treatment Planning

9 Chapter 9: Patient Care: Treatment Monitoring & Outcomes

9.1 Patient Counseling, Education, & Adherence 9.2 Treatment Monitoring: Efficacy, Targets, & Lab Interpretation 9.3 Adverse Drug Event (ADE) Detection & Management

10 Chapter 10: Professional Practice & Evidence-Based Medicine

10.1 Research Methodology & Biostatistics 10.2 Drug Literature Evaluation & Evidence-Based Application 10.3 Medication Safety, Quality of Care, & Public Health

11 Chapter 11: Professional Practice: Systems & Management

11.1 Healthcare Regulations, Standards of Care, & Collaborative Practice 11.2 Pharmacoeconomics, Cost-Benefit Analysis, & Formulary Management

2.3 Critical Care & Emergency Medicine

Key Takeaways Explain This Topic AI

The SSC Hour-1 Bundle dictates immediate lactate measurement, blood cultures, antibiotics, and crystalloid fluids for sepsis.

Norepinephrine is the undisputed first-line vasopressor for septic shock due to its potent alpha-1 activity.

ICU sedation favors light sedation with non-benzodiazepines like propofol or dexmedetomidine to prevent delirium.

N-acetylcysteine (NAC) must be administered rapidly in acetaminophen overdose to replenish hepatic glutathione.

High-Dose Insulin (HDI) therapy is critical for overcoming myocardial insulin resistance in CCB/beta-blocker toxicity.

Last updated: July 2026

  • Critical Care & Emergency Medicine
  • Sepsis and Septic Shock (Surviving Sepsis Campaign)

The Surviving Sepsis Campaign (SSC) guidelines outline a time-critical, evidence-based approach to managing sepsis and septic shock, aiming to halt progression to multi-organ failure. The initial "Hour-1 Bundle" demands immediate execution:

Measure lactate levels (re-measure within 2-4 hours if initial is > 2 mmol/L to ensure clearance).

Obtain blood cultures prior to antibiotic administration, taking care not to delay antibiotics by more than 45 minutes if cultures are difficult to obtain.

Administer broad-spectrum empiric IV antibiotics (covering MRSA and Pseudomonas based on local antibiograms).

Begin rapid administration of 30 mL/kg of crystalloid fluid for hypotension or lactate ≥ 4 mmol/L.

Apply vasopressors if hypotensive during or after fluid resuscitation to maintain a Mean Arterial Pressure (MAP) ≥ 65 mmHg.

Fluid Resuscitation and Vasoactive Agents :

Balanced crystalloids (e.g., Lactated Ringer's, Plasma-Lyte) are preferred over 0.9% normal saline, as large volumes of normal saline can cause hyperchloremic non-anion gap metabolic acidosis, leading to renal vasoconstriction and acute kidney injury. Fluid responsiveness should be guided by dynamic measures (e.g., passive leg raise, stroke volume variation) rather than static CVP.

For vasoactive support, Norepinephrine is the undisputed first-line vasopressor in septic shock. It exhibits potent alpha-1 agonism (profound vasoconstriction) with modest beta-1 agonism (inotropic support without excessive tachycardia).

If MAP remains < 65 mmHg despite adequate norepinephrine (typically reaching 0.25-0.5 mcg/kg/min), Vasopressin (up to 0.03 units/min) is the recommended second-line agent. Vasopressin acts on V1 receptors and serves a vasopressor-sparing role, replacing endogenous vasopressin stores depleted during shock. Epinephrine is considered a third-line option.

Dobutamine (a potent beta-1 agonist) should be added only if there is evidence of persistent hypoperfusion and cardiac dysfunction (e.g., low cardiac output or elevated filling pressures) despite adequate fluid loading and vasopressors. Angiotensin II (Giapreza) is a novel synthetic vasopressor that can be used for refractory vasodilatory shock but carries a significant risk of thromboembolic events, requiring concurrent VTE prophylaxis.

In patients with refractory septic shock (ongoing requirement for vasopressors despite adequate fluid resuscitation), IV hydrocortisone 200 mg per day (typically 50 mg IV every 6 hours) is recommended to treat critical illness-related corticosteroid insufficiency (CIRCI).

Analgesia, Sedation, and Delirium (PADIS Guidelines)

The ICU management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep disruption (PADIS) focuses on achieving patient comfort while facilitating liberation from mechanical ventilation.

Analgesia-First Approach : Pain must be assessed (using CPOT or BPS tools) and treated prior to initiating sedatives. IV opioids (fentanyl, hydromorphone) are the mainstay of therapy. Fentanyl has a rapid onset and lacks active metabolites, but its extreme lipophilicity causes it to sequester in adipose tissue, leading to prolonged emergence after continuous infusions. Hydromorphone is preferred in patients with renal dysfunction. Morphine is avoided due to histamine release (hypotension) and accumulation of the active neurotoxic metabolite morphine-6-glucuronide in renal failure.

Sedation Strategies : Light sedation (Richmond Agitation-Sedation Scale [RASS] -1 to -2) is universally recommended over deep sedation, alongside daily spontaneous awakening trials (SATs) and spontaneous breathing trials (SBTs) to reduce the duration of mechanical ventilation. Non-benzodiazepine sedatives are strongly preferred.

Propofol : A highly lipid-soluble, rapid-acting GABA agonist. Provides deep sedation and amnesia but no analgesia. Risks include Propofol-Related Infusion Syndrome (PRIS, characterized by metabolic acidosis, rhabdomyolysis, and cardiovascular collapse), hypertriglyceridemia, and dose-dependent hypotension. Triglycerides must be monitored every 3-4 days; the lipid emulsion provides 1.1 kcal/mL, which must be factored into parenteral nutrition calculations.

Dexmedetomidine (Precedex) : A selective centrally-acting alpha-2 agonist providing "cooperative sedation" without depressing respiratory drive. It has mild analgesic-sparing properties. The primary adverse effects are bradycardia and hypotension. It is highly effective for facilitating extubation.

Benzodiazepines (Midazolam, Lorazepam) : Associated with a higher risk of delirium and prolonged mechanical ventilation. Reserved for specific indications such as alcohol withdrawal, status epilepticus, or when propofol/dexmedetomidine are contraindicated. Midazolam has active metabolites that severely accumulate in renal failure.

Delirium : Routine screening is performed using the CAM-ICU tool. Non-pharmacologic interventions (early mobility, sleep hygiene, reorientation) are first-line. Typical and atypical antipsychotics (haloperidol, quetiapine) may be used for hyperactive delirium to prevent self-harm, but they do not reduce delirium duration or mortality, and they require strict QTc monitoring.

Neuromuscular Blocking Agents (NMBAs)

In critically ill patients with severe ARDS (PaO2/FiO2 < 150), a continuous infusion of an NMBA (e.g., cisatracurium) may be utilized for up to 48 hours to improve patient-ventilator synchrony. Cisatracurium is preferred in multi-organ failure because it undergoes Hofmann elimination (spontaneous degradation in plasma dependent on body temperature and pH) and does not rely on renal or hepatic clearance. Patients receiving NMBAs must be deeply sedated (RASS -4 to -5) and receive adequate analgesia prior to paralysis. Depth of paralysis is monitored using a Train-of-Four (TOF) peripheral nerve stimulator.

Acute Toxicology and Antidotes

Rapid identification of toxidromes and appropriate antidote administration is critical for survival.

Toxin/Overdose Antidote Mechanism and Pearls

Acetaminophen (APAP) N-acetylcysteine (NAC) APAP overdose depletes glutathione, leading to the buildup of the toxic metabolite NAPQI, which causes hepatocyte necrosis. NAC replenishes glutathione stores. Effectiveness is nearly 100% if administered within 8 hours of ingestion. Treatment is guided by the Rumack-Matthew nomogram, which requires an APAP level drawn at least 4 hours post-ingestion.

Opioids Naloxone Competitive mu-opioid receptor antagonist reversing miosis, respiratory depression, and CNS depression. The half-life of naloxone is short (30-60 mins), meaning patients who overdosed on long-acting opioids (e.g., methadone) require a continuous naloxone infusion to prevent re-narcotization.

Tricyclic Antidepressants (TCAs) Sodium Bicarbonate TCAs cause fatal arrhythmias by blocking fast sodium channels in the myocardium. IV sodium bicarbonate overcomes this blockade, narrowing the QRS complex and improving contractility.

Calcium Channel Blockers / Beta Blockers High-Dose Insulin (HDI) + Glucose Overcomes myocardial insulin resistance to directly improve inotropy. Therapy also requires IV calcium (for CCBs), glucagon (for BBs), and significant vasopressor support.

Ethylene Glycol / Methanol Fomepizole Competitively inhibits alcohol dehydrogenase, preventing the formation of toxic metabolites (glycolic/oxalic acid causing renal failure, or formic acid causing blindness). Hemodialysis is required if severe acidemia or end-organ damage is present.